HAVANA, Cuba, Aug 12 (acn) The new Cuban vaccine for the treatment of chronic hepatitis B is currently undergoing clinical trials in Cuba and eight Asian countries, with the cooperation of the French company Abivax.
Called HeberNasvac, the new product that is administered nasally and subcutaneously, developed by researchers of the Center for Genetic Engineering and Biotechnology (CIGB), has proved to be more effective and safer than the rest of those existing in the world today against the illness.
As informed to Granma newspaper by Iris Lugo, a specialist of the Communication Group of that entity of the business group BioCubaFarma, studies of clinical evaluation have been approved by regulatory authorities in Australia, New Zealand, South Korea, Singapore, Taiwan, Hong Kong , the Philippines and Thailand.
Also, the promising vaccine is supported by patents granted in the most demanding markets and has more than 20 scientific publications by Cuban experts with the cooperation of the Ehime University in Japan; the Society for the Study of the Liver, in Bangladesh; the Pasteur Institute of France; and the University of Hanover, Germany, just to name a few.
It is expected to begin to be used in Cuba in 2016, after obtaining the approval of the sanitary registration granted by the Center for State Control of Medicaments, Equipment and Medical Devices (CECMED).
According to the World Health Organization, chronic liver disease caused by the hepatitis B virus is one of the main causes of liver cancer, liver cirrhosis, and other complications such as esophageal varicose veins. Each year there are on the planet about one million deaths related to infection by this virus.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio